GNH USA

Europe — EMA

Levosimendan Kalceks

GNH USA supplies Levosimendan Kalceks (Levosimendan), a calcium sensitizer / inotropic agent for acute decompensated heart failure and cardiogenic shock.

Levosimendan

Request sourcing

1
Pack/s

What is Levosimendan?

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer / inotropic agent presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Levosimendan used for?

Levosimendan is used in cardiovascular conditions where enhanced cardiac contractility is required.

- Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Cardiogenic shock: stabilises haemodynamics and supports systemic circulation. - Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility to aid recovery.

What are the side effects of Levosimendan?

Levosimendan may be associated with several adverse reactions, which are grouped by frequency.

Common Side Effects: - Hypotension: drop in blood pressure, especially with concurrent vasodilators. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require intervention. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischaemia: chest pain or ECG changes. - Allergic reactions: rash, bronchospasm, or anaphylaxis.

What precautions apply to Levosimendan?

Before initiating levosimendan, clinicians should consider several safety aspects.

- Cardiac monitoring: continuous ECG and blood pressure observation during infusion. - Renal impairment: adjust therapy if severe renal dysfunction is present. - Hepatic impairment: use with caution in patients with significant liver disease. - Electrolyte balance: correct hypokalaemia or hypomagnesemia to reduce arrhythmia risk. - Concomitant vasodilators: monitor closely for additive hypotensive effects. - Store at ambient temperature: keep in original container, protect from light and moisture.

What does Levosimendan interact with?

Levosimendan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Sodium nitroprusside: combined use may cause profound hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive vasodilatory effect. - Strong vasodilators (e.g., nitroglycerin): risk of severe blood pressure fall.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response. - ACE inhibitors or ARBs: can enhance hypotensive response. - Diuretics: may affect intravascular volume and blood pressure. - Digoxin: monitor for signs of excessive inotropy.

Frequently asked questions

What is Levosimendan Kalceks used for?+
Levosimendan Kalceks is an intravenous formulation of levosimendan used primarily to treat acute decompensated heart failure and cardiogenic shock. It helps improve cardiac contractility and reduces vascular resistance, supporting patients who require rapid haemodynamic stabilisation in a hospital setting.
How does levosimendan work?+
Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium concentrations. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that lowers preload and afterload, thereby improving overall cardiac output.
What is the usual dose of levosimendan?+
The dosing regimen for levosimendan is determined by the treating physician based on the patient’s clinical condition, severity of heart failure, and response to therapy. The prescriber will set the infusion rate, duration, and any loading dose according to established guidelines and individual patient needs.
Is levosimendan safe in pregnancy or breastfeeding?+
Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be excluded, the drug should only be used if the potential benefit justifies the possible harm to the fetus or infant, and it is generally avoided unless absolutely necessary.
How do I order Levosimendan Kalceks from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity of Levosimendan Kalceks. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.
How does levosimendan compare with other inotropic agents?+
Unlike traditional calcium‑increasing inotropes, levosimendan enhances contractility by sensitising troponin C to existing calcium, which reduces the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that can be advantageous over agents such as dobutamine or dopamine in certain clinical scenarios.
What are the storage and handling requirements for Levosimendan Kalceks?+
Levosimendan Kalceks should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. The solution must be inspected for particulate matter or discoloration before administration, and any unused portion should be discarded according to local regulations.
How is Levosimendan Kalceks administered?+
Levosimendan Kalceks is given as an intravenous infusion under continuous cardiac and haemodynamic monitoring. The infusion may be started with or without a loading dose, followed by a maintenance infusion over several hours, as directed by the prescribing clinician based on the patient’s response and tolerance.
What are the most serious risks to watch for while receiving levosimendan?+
The most serious adverse events include severe hypotension, ventricular arrhythmias, myocardial ischaemia, and rare allergic reactions such as anaphylaxis. Clinicians should monitor blood pressure, heart rhythm and ECG changes closely throughout the infusion and be prepared to intervene promptly if any of these complications arise.
Who should not use levosimendan?+
Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals with significant obstructive cardiac lesions where increased contractility could be harmful. Caution is also advised in patients with severe renal or hepatic impairment, and it should be avoided in pregnancy unless absolutely necessary.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Levosimendan
Route
Intravenous Use
Manufacturer
Kalceks
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU